PhaseBio goes public in downsized offering of $46 million
The company, developing a reversal agent for an antiplatelet therapy in-licensed from AstraZeneca, had proposed an IPO at $12-14 per share.
The company, developing a reversal agent for an antiplatelet therapy in-licensed from AstraZeneca, had proposed an IPO at $12-14 per share.